Ensign Peak Advisors, Inc Alkermes Plc. Transaction History

Ensign Peak Advisors, Inc

$55.3 Billion
Q4 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 62,916 shares of ALKS stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,916

Previous 62,916 -0.0%

Holding current value

$2.18 Million

Previous $1.76 Million 2.73%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $288,545 - $358,017	-12,540 Reduced 16.62%	62,916 $1.76 Million
Q2 2024 Aug 13, 2024	SELL	$23.21 - $27.24 $498,550 - $585,115	-21,480 Reduced 22.16%	75,456 $1.82 Million
Q1 2024 May 14, 2024	SELL	$26.4 - $32.56 $7.84 Million - $9.67 Million	-297,004 Reduced 75.39%	96,936 $2.62 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $206,380 - $253,273	-8,831 Reduced 2.19%	393,940 $10.9 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $258,631 - $304,322	-9,519 Reduced 2.31%	402,771 $11.3 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $196,537 - $233,224	6,935 Added 1.71%	412,290 $12.9 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $1.32 Million - $1.57 Million	59,959 Added 17.36%	405,355 $10.6 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $1.34 Million - $1.95 Million	61,116 Added 21.5%	345,396 $7.71 Million
Q2 2022 Aug 12, 2022	BUY	$26.4 - $30.54 $6.69 Million - $7.74 Million	253,280 Added 817.03%	284,280 $8.47 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $21,455 - $26,030	930 Added 3.09%	31,000 $816,000
Q4 2021 Feb 11, 2022	BUY	$21.47 - $32.08 $645,602 - $964,645	30,070 New	30,070 $699,000

Others Institutions Holding ALKS

# of Institutions

376

Shares Held

173M

Call Options Held

231K

Put Options Held

158K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.68B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Alkermes Plc. Transaction History